Medable vs OpenAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Medable raised $304M to build the leading decentralized clinical trial (DCT) platform, enabling remote patient participation, eConsent, and wearable data integration for pharmaceutical trials.
About
Medable provides the technology infrastructure for decentralized clinical trials (DCTs) — enabling pharmaceutical companies to conduct trials where patients participate from home rather than traveling to research sites. The platform covers the full DCT workflow: electronic informed consent (eConsent), remote patient monitoring via wearables, telemedicine visits, electronic clinical outcome assessments (eCOA), and direct-to-patient drug delivery coordination.
GPT-5 and o3 model family at $25B+ ARR; $840B post-money valuation (Feb 2026 round); ChatGPT 1B+ users; largest private fundraise in history ($110B). Competing with Anthropic Claude 4, Google Gemini 3, Meta Llama 4.
About
OpenAI is a San Francisco-based artificial intelligence company developing and deploying large-scale AI systems — including GPT-4o, o1 reasoning models, DALL-E 3 image generation, Sora video generation, and the Whisper speech recognition model — through the ChatGPT consumer product and OpenAI API for developers and enterprise customers. Founded in 2015 as a nonprofit by Sam Altman, Elon Musk, Greg Brockman, and others and restructured into a capped-profit company, OpenAI raised $157 billion in total funding including a $6.6 billion round in October 2024 at a $157 billion valuation and a $40 billion round from SoftBank in 2025, generating $3.7 billion in annualized revenue in 2024 with 400 million weekly ChatGPT users.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.